Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial: A randomized clinical trial

Lisbeth Marianne Thøstesen; Jesper Kjaergaard; Gitte Thybo Pihl; Nina Marie Birk; Thomas Nørrelykke Nissen; Peter Aaby; Aksel Karl Georg Jensen; Annette Wind Olesen; Lone Graff Stensballe; Dorthe Lisbeth Jeppesen; Christine Stabell Benn; Poul-Erik Kofoed

doi:10.1111/all.13314

Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial: A randomized clinical trial

Lisbeth Marianne Thøstesen
, Jesper Kjaergaard
, Gitte Thybo Pihl
, Nina Marie Birk
, Thomas Nørrelykke Nissen
, Peter Aaby
, Aksel Karl Georg Jensen
, Annette Wind Olesen
, Lone Graff Stensballe
, Dorthe Lisbeth Jeppesen
, Christine Stabell Benn
, Poul-Erik Kofoed

Sygeplejerskeuddannelsen i Vejle

Department of Clinical Immunology and Biochemistry, Lillebaelt Hospital, Vejle, Denmark.
Copenhagen University Hospital
Statens Serum Institut
University of Southern Denmark

Research output: Contribution to journal › Journal article › Research › peer-review

Abstract

BACKGROUND: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.

METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.

RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).

CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).

Original language	English
Journal	Allergy: European Journal of Allergy and Clinical Immunology
Volume	73
Issue number	2
Pages (from-to)	498-504
Number of pages	7
ISSN	0105-4538
DOIs	https://doi.org/10.1111/all.13314
Publication status	Published - Feb 2018

Keywords

disease, health science and nursing

Access to Document

10.1111/all.13314Licence: Other

Cite this

Thøstesen, L. M., Kjaergaard, J., Pihl, G. T., Birk, N. M., Nissen, T. N., Aaby, P., Jensen, A. K. G., Olesen, A. W., Stensballe, L. G., Jeppesen, D. L., Benn, C. S., & Kofoed, P.-E. (2018). Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial: A randomized clinical trial. Allergy: European Journal of Allergy and Clinical Immunology, 73(2), 498-504. https://doi.org/10.1111/all.13314

@article{b015e928a0ac4b4181823b8be3cc100d,

title = "Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial: A randomized clinical trial",

abstract = "BACKGROUND: Studies have suggested that Bacillus Calmette-Gu{\'e}rin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7\%) children in the BCG group and 495/1,952 (25.4\%) children in the control group (RR = 0.90 [95\% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).",

keywords = "disease, health science and nursing",

author = "Th{\o}stesen, \{Lisbeth Marianne\} and Jesper Kjaergaard and Pihl, \{Gitte Thybo\} and Birk, \{Nina Marie\} and Nissen, \{Thomas N{\o}rrelykke\} and Peter Aaby and Jensen, \{Aksel Karl Georg\} and Olesen, \{Annette Wind\} and Stensballe, \{Lone Graff\} and Jeppesen, \{Dorthe Lisbeth\} and Benn, \{Christine Stabell\} and Poul-Erik Kofoed",

note = "{\textcopyright} 2017 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.",

year = "2018",

month = feb,

doi = "10.1111/all.13314",

language = "English",

volume = "73",

pages = "498--504",

journal = "Allergy: European Journal of Allergy and Clinical Immunology",

issn = "0105-4538",

publisher = "John Wiley and Sons Ltd",

number = "2",

}

Thøstesen, LM, Kjaergaard, J, Pihl, GT, Birk, NM, Nissen, TN, Aaby, P, Jensen, AKG, Olesen, AW, Stensballe, LG, Jeppesen, DL, Benn, CS & Kofoed, P-E 2018, 'Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial: A randomized clinical trial', Allergy: European Journal of Allergy and Clinical Immunology, vol. 73, no. 2, pp. 498-504. https://doi.org/10.1111/all.13314

Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial: A randomized clinical trial. / Thøstesen, Lisbeth Marianne; Kjaergaard, Jesper; Pihl, Gitte Thybo et al.
In: Allergy: European Journal of Allergy and Clinical Immunology, Vol. 73, No. 2, 02.2018, p. 498-504.

Research output: Contribution to journal › Journal article › Research › peer-review

TY - JOUR

T1 - Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial

T2 - A randomized clinical trial

AU - Thøstesen, Lisbeth Marianne

AU - Kjaergaard, Jesper

AU - Pihl, Gitte Thybo

AU - Birk, Nina Marie

AU - Nissen, Thomas Nørrelykke

AU - Aaby, Peter

AU - Jensen, Aksel Karl Georg

AU - Olesen, Annette Wind

AU - Stensballe, Lone Graff

AU - Jeppesen, Dorthe Lisbeth

AU - Benn, Christine Stabell

AU - Kofoed, Poul-Erik

PY - 2018/2

Y1 - 2018/2

N2 - BACKGROUND: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).

AB - BACKGROUND: Studies have suggested that Bacillus Calmette-Guérin (BCG) vaccination may reduce the risk of allergic diseases, including atopic dermatitis.METHODS: The Danish Calmette Study was conducted 2012-2015. Within 7 days of birth new-borns were randomised 1:1 to BCG or no BCG. Exclusion criteria were gestational age <32 weeks, birth weight <1000 g, known immunodeficiency or no Danish-speaking parent. Data were collected through telephone interviews and clinical examinations until 13 months.RESULTS: Clinical atopic dermatitis was diagnosed in 466/2,052 (22.7%) children in the BCG group and 495/1,952 (25.4%) children in the control group (RR = 0.90 [95% confidence intervals 0.80-1.00]). The effect of neonatal BCG vaccination differed significantly between children with atopic predisposition (RR 0.84 (0.74-0.95)) and children without atopic predisposition (RR 1.09 [0.88-1.37]) (test of no interaction, P = .04).CONCLUSION: Among children with atopic predisposition, the number-needed-to-treat with BCG to prevent one case of atopic dermatitis was 21 (12-76).

KW - disease, health science and nursing

UR - http://www.mendeley.com/research/neonatal-bcg-vaccination-atopic-dermatitis-before-13-months-age-randomized-clinical-trial

U2 - 10.1111/all.13314

DO - 10.1111/all.13314

M3 - Journal article

C2 - 28929567

SN - 0105-4538

VL - 73

SP - 498

EP - 504

JO - Allergy: European Journal of Allergy and Clinical Immunology

JF - Allergy: European Journal of Allergy and Clinical Immunology

IS - 2

ER -

Neonatal BCG vaccination and atopic dermatitis before 13 months of age: A randomized clinical trial: A randomized clinical trial

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this